Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), RxSight (RXST) and Cardiff Oncology (CRDF)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on IQVIA Holdings (IQV – Research Report), RxSight (RXST – Research Report) and Cardiff Oncology (CRDF – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IQVIA Holdings (IQV)
In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on IQVIA Holdings. The company’s shares closed last Thursday at $164.79.
According to TipRanks.com, Singh ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for IQVIA Holdings with a $227.31 average price target, which is a 37.3% upside from current levels. In a report issued on February 15, TipRanks – PerPlexity also upgraded the stock to Buy with a $193.00 price target.
See the top stocks recommended by analysts >>
RxSight (RXST)
In a report released today, Steven Lichtman from William Blair maintained a Hold rating on RxSight. The company’s shares closed last Thursday at $8.59.
According to TipRanks.com, Lichtman is a 5-star analyst with an average return of
RxSight has an analyst consensus of Hold, with a price target consensus of $10.14, which is a 33.2% upside from current levels. In a report issued on February 18, BTIG also maintained a Hold rating on the stock.
Cardiff Oncology (CRDF)
Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Cardiff Oncology today and set a price target of $12.00. The company’s shares closed last Thursday at $1.91.
According to TipRanks.com, LeBoyer is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cardiff Oncology with a $9.33 average price target, which is a 430.1% upside from current levels. In a report issued on February 24, TD Cowen also maintained a Buy rating on the stock.
